
Pascal Bonnet
Professeur de Chimie ; Vice-Président de la Recherche de l'Université d'Orléans
53
Documents
Affiliations actuelles
- Institut de Chimie Organique et Analytique (ICOA)
- Université d'Orléans (UO)
Identifiants chercheurs
Publications
14
8
3
2
2
1
1
1
1
1
1
49
3
1
1
Publications
Synthesis and preclinical validation of LIMKs inhibitors: Promising drugs for osteosarcoma treatment?XXVII EFMC International Symposium on Medicinal Chemistry, Sep 2022, NICE, France
Communication dans un congrès
hal-04823073
v1
|
|
Synthesis and preclinical validation of LIMKs inhibitors: Promising drugs for osteosarcoma treatment?SCT 29th Young Research Fellow Meeting, Jul 2022, Nantes, France
Communication dans un congrès
hal-04822252
v1
|
|
|
Conception of DYRK1A kinase inhibitors via metal-catalyzed C-H arylation, inspired by fragment-growing studiesInternational Electronic Conference on Medicinal Chemistry (ECMC, 4, 2018), Jean-Jacques Vanden Eynde (coord.), Nov 2018, [online], Belgium. ⟨10.3390/ecmc-4-05580⟩
Communication dans un congrès
hal-02383907
v1
|
Développement de petites molécules inhibitrices des LIM kinases, nouvelles cibles thérapeutiques pour lutter contre le cancer, les maladies neurologiques et la neurofibromatoseJournée Fédération CBM-ICOA, Jan 2018, Orléans, France
Communication dans un congrès
hal-02928530
v1
|
|
|
PrePeP – A Tool for the Identification and Characterization of Pan Assay Interference Compounds24th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining, Aug 2018, Londres, United Kingdom. pp.462-471, ⟨10.1145/3219819.3219849⟩
Communication dans un congrès
hal-01939468
v1
|
Fragment covalent docking (FCD) approach: An innovative in silico tools for the prediction of peptide-protein interaction256th National Meeting and Exposition of the American-Chemical-Society Nanoscience, Nanotechnology and Beyond (ACS), American Chemical Society (ACS). USA., Aug 2018, Boston, United States. pp.2
Communication dans un congrès
hal-02734800
v1
|
|
Neurofibromatosis type I: from basic to applied research4th LIA Workshop, Jun 2017, Cracovie, Poland
Communication dans un congrès
hal-02928517
v1
|
Development of small molecule inhibitors of LIM kinases, new therapeutic targets to treat Neurofibromatosis type IJoint Global Neurofibromatosis Conference 2018, Nov 2018, Paris, France
Poster de conférence
hal-02924077
v1
|
|
LIM Kinases: new anticancer therapeutic targetsBreast Cancer Symposium, Jun 2017, Nantes, France
Poster de conférence
hal-03680148
v1
|
|
LIM kinases: new therapeutic targets to treat Neurofibromatosis type IThe 7th EMBO meeting, Sep 2016, Mannheim, Germany.
Poster de conférence
hal-02453490
v1
|
|
Computational study of ligand-receptor binding process using enhanced molecular dynamics simulations21st European Symposium on Quantitative Structure-Activity Relationship, Sep 2016, Vérone, Italy
Poster de conférence
hal-02919149
v1
|
|
Projet Région LiCorNe: LIMK protein inhibitors, new therapeutic agents for treatment of cognitive disorders associated with type I NeurofibromatosisJournée Fédération PCV FR2708, Jan 2016, Orléans, France
Poster de conférence
hal-02924056
v1
|
4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancerFrance, Patent n° : WO2021239727 A1. AMV. 2021
Brevet
hal-03555349
v1
|
Chargement...
Chargement...